Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Frontiers in Systems Biology
|
August 14, 2025
Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its <i>pAIns</i> and <i>gAIns</i>
Núria Folguera-Blasco, Florencia A T Boshier, Aydar Uatay, et al.
Journal of Clinical Pharmacology
|
November 7, 2017
Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
Richard G Langley, Sree Kasichayanula, Mona Trivedi, et al.
Cancer Chemotherapy and Pharmacology
|
January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
Aburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology
|
June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma
KyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
British Journal of Clinical Pharmacology
|
November 10, 2025
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma
Shankar Lanke, Kowser Miah, Damilola Olabode, et al.
Clinical and Translational Science
|
February 15, 2026
Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches
Zoey Tang, KyoungSoo Lim, Yu Jiang, et al.
Clinical Pharmacology and Therapeutics
|
July 8, 2023
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Michelle Green, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 2023
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study
Jimmy Zhijian He, Vincent Duval, Petra Jauslin, et al.
Journal of Clinical Pharmacology
|
February 28, 2023
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors
Michael Hwang, Chunling Fan, Mun Sang Yue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Frontiers in Systems Biology
|
August 14, 2025
Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its <i>pAIns</i> and <i>gAIns</i>
Núria Folguera-Blasco, Florencia A T Boshier, Aydar Uatay, et al.
Journal of Clinical Pharmacology
|
November 7, 2017
Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
Richard G Langley, Sree Kasichayanula, Mona Trivedi, et al.
Cancer Chemotherapy and Pharmacology
|
January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
Aburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology
|
June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma
KyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
British Journal of Clinical Pharmacology
|
November 10, 2025
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma
Shankar Lanke, Kowser Miah, Damilola Olabode, et al.
Clinical and Translational Science
|
February 15, 2026
Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches
Zoey Tang, KyoungSoo Lim, Yu Jiang, et al.
Clinical Pharmacology and Therapeutics
|
July 8, 2023
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Michelle Green, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 2023
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study
Jimmy Zhijian He, Vincent Duval, Petra Jauslin, et al.
Journal of Clinical Pharmacology
|
February 28, 2023
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors
Michael Hwang, Chunling Fan, Mun Sang Yue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
Page
of 2